Core Viewpoint - The innovative skin treatment product "Fumeida" developed by Zhejiang Funuo Pharmaceutical Co., Ltd. faces trademark challenges from ExxonMobil, which may hinder its market launch despite receiving approval from the National Medical Products Administration of China [2][4]. Group 1: Product and Approval - "Fumeida" (Fluocinolone Hydroquinone Tretinoin Cream) is a new generation topical treatment for melasma and is the first domestic product that meets international gold standards with a three-component formula [2]. - The product has been in development for over ten years and has recently received approval for market launch [2]. Group 2: Trademark Dispute - ExxonMobil has applied to the Chinese National Intellectual Property Administration to declare the "Fumeida" trademark invalid, claiming it is similar to their "Mobil" trademark, alleging potential consumer deception [2][4]. - Funuo Pharmaceutical registered the "Fumeida" trademark in 2019 and has used it for multiple products, achieving positive social feedback [4]. Group 3: Legal and Industry Implications - The legal representative from Funuo Pharmaceutical argues that the two trademarks differ significantly in terms of text composition, pronunciation, meaning, and overall appearance [6]. - ExxonMobil's strategy of full-category trademark protection allows them to assert rights across different industries, which can lead to disputes with smaller companies like Funuo Pharmaceutical, often resulting in high legal costs and strategic adjustments for the latter [6]. - Funuo Pharmaceutical emphasizes the importance of understanding the differences in trademark characteristics across industries and calls for respect for Chinese language conventions in trademark protection [6][7].